Speciality Medicines IPO Financials
The Speciality Medicines IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Oct 2025, Speciality Medicines Limited reported assets of ₹45.57 crore, revenue of ₹36.93 crore, and a profit after tax (PAT) of ₹6.06 crore. The company had a net worth of ₹36.47 crore and reserves & surplus of ₹30.04 crore, and total borrowings are 4.81 crore.
Revenue increased by 58.52% in 31 Mar 2025 and decreased by 52.75% in 31 Mar 2024, while Profit After Tax (PAT) grew by 42.08% in 31 Mar 2025 and declined by 65.97% in 31 Mar 2024, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Speciality Medicines Limited Financials (₹ in Crores)
| Particular | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Revenue | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| Net Worth | 36.47 | 30.42 | 15.06 |
| Reserve & Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowings | 4.81 | 5.05 | 2.86 |
EPS Pre
13.38%
EPS Post
11.82%
P/E Pre
9.27
P/E (Post Issue)
10.49x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Speciality Medicines Limited?
Speciality Medicines Limited reported revenue of ₹36.93 crore as of 31 Oct 2025. Revenue figures from the Speciality Medicines IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Speciality Medicines Limited?
Speciality Medicines Limited reported a Profit After Tax (PAT) of ₹6.06 crore as of 31 Oct 2025. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Speciality Medicines Limited?
Speciality Medicines Limited has a Price-to-Earnings (P/E) ratio of 9.27x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.